The following Life Sciences practice note Produced in partnership with Vincenzo Salvatore of BonelliErede provides comprehensive and up to date legal information covering:
In recent years, we have witnessed a constantly growing interest from all stakeholders (the general public, patients associations, physicians, pharmaceutical industry and academia alike) to get access to information concerning medicinal products. Under this pressure, both legislators and medicines regulatory authorities have moved towards a more generous approach giving access to a larger set of documents and information related to the quality, safety and efficacy of medicinal products than ever before. In the EU, the European Medicines Agency (EMA) is the regulatory body responsible for the protection and promotion of human and animal health. Some of the EMA’s key responsibilities include the scientific evaluation of applications for marketing authorisation (MA) of medicines through the centralised procedure and the co-ordination of the EU pharmacovigilance system for the monitoring of the safety of medicinal products. The EMA therefore holds a large volume of scientific and clinical data on medicines. There are several channels through which documents and information on medicinal products can be accessed. These can broadly be summarised as the following:
via a request for access to certain documents to the regulatory authority that hold those documents
following a release pursuant to legal obligations, eg the rules governing clinical trials which mandate that certain information be made publicly available via the clinical trial database or the rules on authorisation of medicines which mandates that public
**Trials are provided to all LexisPSL and LexisLibrary content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Take a free trial
This Practice Note considers the different categories of contractual damages that may be available for financial loss (pecuniary loss), ie expectation-based damages, reliance-based damages and gains-based damages.For guidance on contractual damages generally, see Practice Note: Contractual
When is quantum meruit and quantum valebat relevant?Claims in quantum meruit (value of services) and quantum valebat (value of goods) arise in diverse situations ranging from where contractual terms are silent on issues of payment to where there is no contract at all (Serck v Drake & Scull).General
Broadly, the doctrine of overreaching enables purchasers (which includes tenants and mortgagees) in good faith for money or money’s worth to rely solely on the legal title. In the case of registered land, this means the entries entered on the register of title, as it records ownership of the legal
This Practice Note examines:•why negative pledge clauses are used in commercial transactions •the consequences of breaching negative pledge provisions•how negative pledges are viewed in the context of security and quasi-security, and•key considerations when drafting a negative pledge clauseWhere
0330 161 1234
To view our latest legal guidance content,sign-in to Lexis®PSL or register for a free trial.